Business Context and Reporting Period
Pliant Therapeutics, Inc. (PLRX) filed a Form 8-K on May 11, 2026, to announce financial results for the first quarter ended March 31, 2026. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing text does not provide data to compare current period results against prior comparable periods. No specific material changes are detailed in the body of this 8-K.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, and unusual items are not detailed in the provided text. The report directs readers to the press release (Exhibit 99.1) for the full announcement. The filing includes a standard disclaimer that the information is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 11, 2026) for actual Q1 2026 financial figures.
- Verify cash runway and burn rate details in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the company remains an emerging growth company and its election status regarding extended transition periods.